Pathogenesis of diabetic nephropathy

Journal of Diabetes Investigation

Volumn 2, Issue 4, 2011, Pages 243-247

  Cao, Zemin ^a   Cooper, Mark E ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Angiotensin converting enzyme 2; Cell division autoantigen 1; Reactive oxygen species

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN CONVERTING ENZYME 2; AUTOANTIGEN; CELL DIVISION AUTOANTIGEN 1; CONNECTIVE TISSUE GROWTH FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; MLN 4760; NEPHRIN; PERINDOPRIL; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ACE2 GENE; ALBUMINURIA; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CDA1 GENE; DIABETIC NEPHROPATHY; GENE; GENE EXPRESSION; HUMAN; KIDNEY INJURY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; SHORT SURVEY;

EID: 84859810282     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00131.x     Document Type: Short Survey

References (24)

1. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219.
2. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957-1972.
3. Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens 2010; 20: 62-68.
4. Burrell LM, Johnston CI, Tikellis C, et al. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 2004; 15: 166-169.
5. Koitka A, Cooper ME, Thomas MC, et al. Angiotensin converting enzyme 2 in the kidney. Clin Exp Pharmacol Physiol 2008; 35: 420-425.
6. Thomas MC, Pickering RJ, Tsorotes D, et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res 2010; 107: 888-897.
7. Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005; 26: 369-375; discussion 322-324.
8. Tikellis C, Bialkowski K, Pete J, et al. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 2008; 57: 1018-1025.
9. Tikellis C, Johnston CI, Forbes JM, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41: 392-397.
10. Frojdo S, Sjolind L, Parkkonen M, et al. Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy. Diabetologia 2005; 48: 2278-2281.
11. Chai Z, Sarcevic B, Mawson A, et al. SET-related cell division autoantigen-1 (CDA1) arrests cell growth. J Biol Chem 2001; 276: 33665-33674.
12. Tu Y, Wu W, Wu T, et al. Antiproliferative autoantigen CDA1 transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathways. J Biol Chem 2007; 282: 11722-11731.
13. Ito T, Tsukumo S, Suzuki N, et al. A constitutively active arylhydrocarbon receptor induces growth inhibition of jurkat T cells through changes in the expression of genes related to apoptosis and cell cycle arrest. J Biol Chem 2004; 279: 25204-25210.
14. Radke JR, Donald RG, Eibs A, et al. Changes in the expression of human cell division autoantigen-1 influence Toxoplasma gondii growth and development. PLoS Pathog 2006; 2: e105.
15. Toh BH, Tu Y, Cao Z, et al. Role of cell division autoantigen 1 (CDA1) in cell proliferation and fibrosis. Genes 2010; 1: 335- 348.
16. Pham Y, Tu Y, Wu T, et al. Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-beta in a murine diabetic model of atherosclerosis. Diabetologia 2010; 53: 170-179.
17. Tu Y, Wu T, Dai A, et al. Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor-beta in diabetic nephropathy. Kidney Int 2011; 79: 199-209.
18. Bonnet F, Cooper ME, Kawachi H, et al. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001; 44: 874- 877.
19. Bonnet F, Tikellis C, Kawachi H, et al. Nephrin expression in the post-natal developing kidney in normotensive and hypertensive rats. Clin Exp Hypertens 2002; 24: 371- 381.
20. Forbes JM, Bonnet F, Russo LM, et al. Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria. J Hypertens 2002; 20: 985-992.
21. Cao Z, Bonnet F, Candido R, et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 2002; 13: 1773-1787.
22. Davis BJ, Cao Z, de Gasparo M, et al. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens 2003; 21: 209-216.
23. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57: 1446-1454.
24. Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. Inhibition of NADPH oxidase prevents advanced glycation end productmediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008; 57: 460-469.